Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 in Intermediate/High-risk Myelofibrosis
NCT07551427Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rovadicitinib in myelofibrosis (MF), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Proportion of subjects with >=35% reduction in spleen volume from baseline at 24 weeks, Peak concentration and 8 more. Started Jun 2026; status: recruiting.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07551427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551427.